A new federal ruling means that patients will no longer have access to cheaper versions of Eli Lilly weight loss and diabetes ...

You can reach Katie on Signal at palmer.01. Amid ongoing battles over alternate supplies of blockbuster weight loss drugs, Eli Lilly filed new lawsuits against four telehealth firms and their ...

Eli Lilly has escalated its legal offensive against compounding pharmacies accused of selling unauthorized copies of its blockbuster diabetes and weight-loss drugs containing tirzepatide, the active ...

Following a similar decision in case the trade group Outsourcing Facilities Association brought against FDA over its decision ...

Branded drug manufacturers, including Eli Lilly and Company (Eli Lilly), have been pursuing various legal actions against compounding pharmacies ...

Amid ongoing battles over alternate supplies of blockbuster weight loss drugs, Eli Lilly filed new lawsuits against four telehealth firms and their affiliates, but is using a new line of attack ...

Eli Lilly has unleashed another wave of litigation against four telehealth brands in its widening legal war with sellers of alternative versions of its popular diabetes and weight-loss drugs.

Eli Lilly is throwing legal punches in a pharmaceutical showdown over tirzepatide, its prized ingredient in diabetes and weight-loss treatments. The company filed lawsuits against four ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other other firms that ended the week strong. The stock market ended the shortened trading ...

What a difference five years can make. Just look at Eli Lilly (NYSE: LLY). In April 2020, the drugmaker stood in the shadows to some extent with companies including Johnson & Johnson, Pfizer ...

Eli Lilly, for its part, sells tirzepatide as Mounjaro and Zepbound for diabetes and obesity, respectively. In addition, retatrutide is Lilly’s next-generation weight loss candidate.

While arch rival Eli Lilly and Company (LLY) spent most of the past two years innovating and catching up with the NVO’s dominance, it still wasn’t sufficient to surpass the Danish biopharma ...